This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.
| Item | Details |
|---|---|
| A. Classification codes | ICD-10: E34.8 (Other specified endocrine disorders — Progeria) | OMIM: 176670 (Hutchinson-Gilford progeria syndrome, HGPS) | Gene: LMNA (1q22) | Special Copayment Reduction: V166 (rare disease) | ※ Same ICD-10 code as pineal gland dysfunction, but a separate disease. |
| B. Synonyms | Hutchinson-Gilford progeria syndrome (HGPS), Progeria, childhood progeria, Progeroid laminopathy, Hutchinson-Gilford syndrome |
| C. Adult onset | Adult onset: none — symptoms appear within the first 1–2 years of life. Mean age at death 14.6 years (range 8–20 years). Survival into adulthood extremely rare. |
| 1. History | 1886 first described by Jonathan Hutchinson → 1897 further described·named by Hastings Gilford → 2003 LMNA gene c.1824C>T variant (progerin) identified → clinical trials of a farnesyltransferase inhibitor (lonafarnib) and FDA approval in 2020. |
| 2. Causes | Synonymous variant c.1824C>T (p.G608G) of the LMNA gene (1q22) → aberrant splicing → production of an abnormal lamin A protein with a 50-amino-acid deletion, 'progerin'. |
| 3. Genetics | Almost always a new mutation (de novo). The c.1824C>T variant in LMNA exon 11 in most cases (about 90%). Autosomal dominant; no carrier parents. A few cases of parental mosaicism reported. |
| 4. General epidemiology | Incidence about 1/18,000,000–1/20,000,000 births. Currently about 400 patients worldwide. No differences by sex·race. Very few cases reported in Korea. |
| 5. Pathophysiology | Accumulation of progerin (abnormal lamin A) at the inner nuclear membrane → abnormal nuclear shape·nuclear envelope disruption → activation of DNA damage response·delayed repair → chromatin abnormalities → accelerated cellular senescence → selective damage to mesenchymal cells (vascular smooth muscle cells, adipocytes, osteocytes, etc.). |
| 6. Symptoms | First 1–2 years of life: failure to thrive, lipoatrophy, characteristic face (microcephaly, beaked nose, small face). Progression: alopecia, fat loss, skin sclerosis, joint flexion contractures, decreased bone density, progressive atherosclerosis. Death: myocardial infarction·stroke (mean 14.6 years). |
| 7. Signs | Short stature (mean adult height about 100cm), underweight, loss of subcutaneous fat, shiny·atrophic skin, prominent veins, aged-looking face, joint contractures, high-pitched voice, increased carotid IMT, bone dysplasia on skull X-ray. |
| 8. Screening | No standard neonatal screening test. LMNA gene testing when a characteristic phenotype (failure to thrive + lipoatrophy + characteristic face) is found. Fetal genetic testing possible in case of recurrence within a family (rare). |
| 9. Diagnosis | Clinical diagnosis (characteristic phenotype) + molecular confirmation of LMNA gene c.1824C>T. Detection of progerin protein (immunofluorescence·Western blot). Cardiovascular imaging (carotid ultrasound, echocardiography, coronary CT). |
| 10. Treatment | Lonafarnib (farnesyltransferase inhibitor, FDA approved in 2020): survival extended by 2.5 years. Low-dose aspirin, statins. Under investigation: hematopoietic stem cell transplantation, mRNA-targeted therapy (dual antisense oligonucleotides). Supportive therapy: physical therapy, nutrition, cardiovascular management. |
| 11. Prognosis | Mean age at death 14.6 years; main causes of death myocardial infarction·stroke. Lonafarnib treatment extends survival by a mean of 2.5 years. Cognitive function remains normal and schooling is possible. |
| 12. Prevention | Mostly new mutations, so prevention is not possible. Genetic counseling (very low recurrence risk). Prevention of cardiovascular complications after diagnosis: aspirin·statins, exercise, nutritional management. Early administration of lonafarnib recommended. |
| 13. References | Gordon LB et al. Lonafarnib treatment in children (2018, NEJM) and 9 others |
The history of progeria dates back to British medicine in the late 19th century. In 1886, the British surgeon and pathologist Jonathan Hutchinson reported a case in which he observed elderly-like skin sclerosis, failure to thrive, fat loss, and a characteristic skull shape in a child only 3.5 years old. Hutchinson intuitively recognized that this symptom complex was an independent disease different from any previously known syndrome, but at the time there was no way to explain its exact cause or mechanism. Eleven years later, in 1897, the British pathologist Hastings Gilford described the syndrome in more detail through additional cases and first used the term progeria, derived from the Greek 'progerus' (prematurely old). It was later named 'Hutchinson-Gilford Progeria Syndrome (HGPS)' after the two physicians.
Throughout the first half of the 20th century, sporadic case reports continued from around the world, but research was difficult because the incidence is extremely low (about 1/18,000,000 births). As a result, for decades progeria remained at the level of clinical description. In the mid-20th century, the syndrome began to attract attention as a model of accelerated normal aging, and aging researchers reported that cellular-level changes similar to normal aging, such as telomere shortening, activation of the DNA damage response, and abnormal nuclear structure, occur early in the cells of HGPS patients.
2003 became a historic turning point in HGPS research. Francis Collins's group at the US National Human Genome Research Institute (NHGRI) and a research team supported by the ProGeria Research Foundation independently discovered the c.1824C>T variant in exon 11 of the LMNA gene in HGPS patients (De Sandre-Giovannoli et al., 2003; Eriksson et al., 2003). Although this variant is apparently a synonymous mutation (the glycine at codon 608 is retained), it was revealed to actually activate a cryptic splice donor site within exon 11, producing an abnormal lamin A protein with a 50-amino-acid deletion — progerin. This discovery is a representative example vividly showing the clinical impact of synonymous variants in rare disease research and has been included in molecular medicine textbooks.
Once the molecular mechanism was elucidated, research toward treatment targets advanced rapidly. When it was revealed that progerin, unlike normal lamin A, is not removed from the inner nuclear membrane but remains permanently farnesylated and thereby accumulates abnormally at the inner nuclear membrane, farnesyltransferase inhibitors (FTIs) attracted attention as a treatment target. Clinical trials began in 2007, and in 2018 Gordon et al. published in the New England Journal of Medicine the results of a large analysis showing that mean survival was extended by about 2.5 years in the lonafarnib (FTI) treatment group. Based on these results, lonafarnib received expedited FDA approval as a treatment for HGPS in November 2020, becoming the first regulator-approved treatment in the history of HGPS.
The cause of HGPS is the c.1824C>T (p.G608G) variant in exon 11 of the LMNA gene (1q22), a single variant commonly found in more than about 90% of HGPS patients worldwide. Because the variant itself is a synonymous variant in which glycine (Gly) at codon 608 changes to Gly, the amino acid sequence of the protein does not change. However, this c.1824C>T variant exposes a cryptic splice donor site within exon 11, activating an alternative splicing pathway that is not normally used. As a result, an abnormal transcript of LMNA mRNA is produced in which 150 nucleotides of exon 11 (corresponding to 50 amino acids) are deleted, and the abnormal lamin A protein translated from it is progerin.
Unlike normal lamin A, progerin does not have its N-terminal farnesyl modification, which interacts with the inner nuclear membrane, removed, and remains permanently farnesylated. In normal lamin A, after the precursor pre-lamin A is farnesylated, the C-terminal 15 amino acids including the farnesyl group are cleaved by the ZMPSTE24 protease, allowing it to detach from the nuclear membrane. However, in progerin the 50 amino acids containing this ZMPSTE24 cleavage site are themselves deleted, so cleavage is impossible, and as a result it is anchored to the inner nuclear membrane with the farnesyl group permanently attached. Progerin abnormally accumulated at the inner nuclear membrane in this way acts as a toxic protein that severely deforms nuclear structure.
Other variants of the LMNA gene can also cause various progeroid phenotypes, collectively called 'laminopathies'. Representative examples include Werner syndrome (adult progeria, WRN gene variants), Cockayne syndrome (ERCC gene variants), and atypical Werner syndrome (another form of LMNA variant). These resemble HGPS in clinical presentation but differ in age of onset, main features, and molecular mechanism. In HGPS, the fact that intelligence and cognitive function remain normal is an important point distinguishing it from other progeroid disorders.
HGPS is classified as an autosomal dominant disease, but in clinical practice virtually all cases arise from new mutations (de novo mutation). Because patients do not survive into adulthood and are infertile, the variant is practically never transmitted to the next generation. Thus it appears suddenly in families with no family history and is understood to result from a germ cell mutation in either parent or a somatic mutation at an early post-implantation stage of development. In extremely rare cases, cases have been reported in which one parent carried the HGPS variant through germline mosaicism and a second affected child was born to the same parents, but this is a very rare exception.
The LMNA gene produces several proteins, including lamin A, lamin C, and lamin AΔ10, through alternative splicing. Lamin A and lamin C form the nuclear lamina, a major component of the inner nuclear membrane, and are involved in various nuclear functions such as maintenance of nuclear shape, chromatin organization, DNA replication, transcriptional regulation, and the DNA damage response. Lamins A and C are type V intermediate filament proteins that form dimers through a coiled-coil structure and interact with inner nuclear membrane proteins (emerin, MAN1, SUN1/2, etc.). The 50-amino-acid deletion of progerin causes severe abnormalities in lamin A polymer formation and nuclear lamina structure.
Besides HGPS, laminopathies due to LMNA variants are associated with diverse clinical phenotypes, including Emery-Dreifuss muscular dystrophy (EDMD), dilated cardiomyopathy (CMD1A), familial partial lipodystrophy (FPLD2, Dunnigan type), and spinal motor neuropathy (HMSN). This shows that lamin A plays important roles in various tissues and that tissue-specific pathology is expressed depending on the location and type of the variant.
HGPS is one of the rarest diseases in the world. The estimated incidence is about 1/18,000,000–1/20,000,000 births, and the number of living patients worldwide at any given time is estimated at about 350–400. This low incidence is because most cases arise from new mutations and genetic transmission does not occur. Owing to diagnostic delay (first diagnosis at a mean of 2–3 years of age) and extremely low awareness, some patients may actually remain undiagnosed. The ProGeria Research Foundation operates a worldwide patient registry and, as of 2023, is following about 500 or more patients.
No racial·ethnic differences in incidence have been reported, and it occurs equally in males and females. It is also very rare in Korea, with only a few cases reported to date. In Korea, management support is provided through the rare disease helpline. Regarding parental age, because it is a single nucleotide substitution due to a new mutation, there is a hypothesis that the risk may be slightly increased with older fathers (paternal age effect), but this has not been statistically verified.
At the center of HGPS pathophysiology is the intracellular toxicity of progerin. Progerin is permanently anchored to the inner nuclear membrane in a farnesylated state and gradually accumulates there with each cell division. The accumulated progerin deforms nuclear shape (atypical nuclear blebbing, lobulation), disturbs interactions between the inner nuclear membrane and chromatin, and causes loss of heterochromatin and abnormal histone methylation. As a result, regulation of gene expression is broadly disrupted.
Abnormal nuclear lamina structure leads to defects in the repair mechanisms for DNA double-strand breaks (DSB). Factors of non-homologous end joining (NHEJ) or homologous recombination (HR) required for DSB repair in normal cells are not properly recruited·activated in nuclei with accumulated progerin, and as a result DNA damage accumulates. This persistent DNA damage signal activates the cellular senescence program via the p53-p21 pathway, and cells convert to a senescence-associated secretory phenotype (SASP), in which they can no longer divide and secrete inflammatory cytokines.
Cytotoxicity due to progerin does not appear equally in all cell types; mesenchymal-derived cells, particularly vascular smooth muscle cells (VSMC), adipocyte precursors, osteocytes, and dermal fibroblasts, are selectively and severely damaged. In contrast, neurons and epithelial cells are relatively preserved. Loss of VSMCs due to progerin accumulation impairs the mechanical stability of the vessel wall and extremely accelerates atherosclerosis. Indeed, postmortem autopsies of HGPS patients confirm severe atherosclerotic changes (intimal thickening, calcification, plaque formation) in the coronary arteries, carotid arteries, and abdominal aorta, far in excess of what would be expected for age.
Impaired adipocyte differentiation causes loss of subcutaneous fat, and osteocyte dysfunction reduces bone density and increases fracture risk. Damage to dermal fibroblasts causes skin sclerosis, loss of elasticity, and shiny skin (scleroderma-like skin). Thus HGPS has value as an 'accelerated aging model' that reproduces, in extremely compressed form over a short period, changes that take decades in normal aging.
Most infants appear normal at birth, and because there are no findings specific to HGPS, diagnosis in the neonatal period is rare. However, in some, slightly low birth weight or scleroderma-like skin changes are observed. The first symptom to appear is failure to thrive, a marked slowing of growth rate within the first 1–2 years of life, with abrupt deviation from the normal growth curve. The rate of gain in height and weight is markedly reduced, so that by age 2 the child is already much smaller than the average for age. At the same time, lipoatrophy progresses, subcutaneous fat is lost, the temples become sunken, and a face that is relatively small compared with the adult-sized skull (beaked shape, prominent forehead, small jaw) becomes conspicuous.
Alopecia progresses with loss of scalp hair·body hair·eyebrows, and the scalp veins become prominent. Skin changes include thinning and loss of elasticity of the dermis with shiny sclerotic skin, and localized scleroderma-like sclerosis appears in some. As joint changes, flexion contractures of the knee·elbow·finger joints progress, producing a characteristic posture (knees bent backward, tendency to genu valgum). Due to abnormal tooth development, permanent teeth may erupt overlapping the primary teeth, or partial anodontia may occur. Skull X-ray shows thinning of the skull, mandibular hypoplasia, and shortened clavicles.
Atherosclerosis progresses asymptomatically and in later stages presents as symptoms of angina, myocardial infarction, and stroke. In some patients, exertional chest pain or syncope is the first cardiovascular symptom. Intelligence remains normal, so patients can attend school, and social development also proceeds appropriately for age.
The anthropometric findings of HGPS patients are very distinctive. Final adult height is markedly reduced, averaging about 100cm, and weight is proportionally low. The body habitus typically has the appearance of a 'little old person', which is the most conspicuous clinical feature of this disease. The face is small relative to the head (craniofacial disproportion), the eyes are large and prominent, the nose is beaked (beaked nose), the ears are small without earlobes, and the jaw is small with crowded dental space. The scalp veins are clearly prominent, and owing to alopecia the scalp is exposed as thin skin.
Cardiovascular testing shows increased carotid intima-media thickness (IMT), atherosclerotic plaque formation, and an increased coronary artery calcium score. Echocardiography may show left ventricular hypertrophy and valvular abnormalities. In the peripheral vessels, vascular sounds in the hands·feet are difficult to auscultate, and increased pulse wave velocity confirms arterial stiffness. On serum testing, HDL cholesterol is normal or low, and LDL and triglycerides are normal or mildly elevated. Inflammatory markers such as CRP are sometimes elevated. Hematological and immunological tests are normal, and diabetes or thyroid dysfunction is generally not present. Increased urinary excretion of hyaluronic acid has been reported on urinalysis.
Newborn screening for HGPS is not currently performed. Owing to the very low incidence and normal findings at birth, early detection in the neonatal period is difficult. Clinical situations in which HGPS is suspected are as follows: first, when unexplained severe failure to thrive within the first 1–2 years of life is observed together with lipoatrophy and skin sclerosis; second, when a characteristic facial appearance (small face, large cranium, beaked nose, small jaw) accompanies failure to thrive; third, when alopecia and joint contractures develop early.
When such clinical suspicion arises, LMNA gene testing (Sanger sequencing for the exon 11 c.1824C>T variant or an NGS panel) is performed immediately. Because a single characteristic variant accounts for most cases, rapid diagnosis is possible with targeted variant testing alone. For families with a recurrence risk, prenatal genetic testing using chorionic villus sampling or amniocentesis is theoretically possible, but because most cases are new mutations, the applicability of prenatal screening is very limited.
Diagnosis of HGPS is made by a combination of characteristic clinical findings and molecular testing of the LMNA gene. As clinical diagnostic criteria, clinical suspicion is strong when there are four or more of (1) failure to thrive manifesting within the first 2 years of life (height below the 3rd percentile), (2) loss of subcutaneous fat, (3) craniofacial features (relatively large cranium, small face, beaked nose, small jaw, absent earlobes), (4) alopecia, (5) skin sclerosis/shininess, (6) joint contractures, and (7) skeletal dysplasia (shortened clavicles, thinning of the skull), with no intellectual disability. Confirmation of the LMNA exon 11 c.1824C>T variant is the standard for molecular confirmation and is performed by Sanger sequencing or targeted NGS.
As a method of confirming progerin expression at the cellular level, after skin biopsy and fibroblast culture, the progerin protein band (slightly smaller molecular weight than wild-type lamin A) is identified by immunofluorescence microscopy or Western blot. Detection using progerin-specific antibodies is possible. Nuclear morphology analysis shows atypical nuclear blebbing and lobulation.
Cardiovascular evaluation is performed at diagnosis and regularly thereafter. It includes carotid ultrasound (IMT, presence of plaque), echocardiography (left ventricular function, valves, wall motion abnormalities), electrocardiography, exercise stress testing (when possible), and coronary CT angiography. Brain MRI is performed when there are prodromal symptoms of stroke or for surveillance of silent cerebral infarction. Bone density is assessed by DXA.
Lonafarnib (brand name Zokinvy) is a farnesyltransferase inhibitor (FTI) whose mechanism is to inhibit farnesylation of progerin, preventing its anchoring to the inner nuclear membrane and reducing progerin-related cellular toxicity. It is given orally at a body surface area-based dose (115mg/m² BID, maximum 150mg/m² BID). In a study by Gordon et al. (2018, NEJM) analyzing 258 HGPS patients, a mean survival extension of 2.5 years was confirmed with lonafarnib treatment. Based on these results, the FDA approved it in November 2020 as the first approved treatment for HGPS.
Major adverse effects include gastrointestinal toxicity (nausea, vomiting, diarrhea, anorexia), nephrotoxicity (mild elevation of serum creatinine, proteinuria), elevated liver enzymes, and bone marrow suppression (leukopenia·thrombocytopenia), most of which can be managed by dose adjustment. However, lonafarnib is not a curative treatment but one that prolongs survival; it slows the progression of atherosclerosis but cannot completely suppress it. Accordingly, combination regimens adding low-dose aspirin and statins (pravastatin or zoledronic acid) to lonafarnib have recently been under further study.
mRNA-targeted therapy with antisense oligonucleotides (ASO) or a dual antisense approach is being actively studied as a strategy to directly correct the splicing variant by blocking use of the aberrant splice site. In animal models, ASOs have been reported to markedly lower progerin mRNA levels and extend lifespan, and clinical trials are under way. Direct correction of the c.1824C>T variant using gene editing (CRISPR-Cas9 or base editing) is also being validated at the cellular level and in mouse models. In addition, autophagy-activating substances such as sulforaphane, which promote the autophagy pathway so that progerin is degraded, are being studied at the preclinical stage.
The mean age at death of untreated HGPS patients is 14.6 years, with a range of 8–20 years. The main causes of death are myocardial infarction (about 75%) and stroke (about 25%) due to atherosclerosis of the coronary or cerebral arteries. This is end-stage cardiovascular disease appearing in childhood, requiring clinicians to pay particular attention to cardiovascular signs in patients of this age group. In patients treated with lonafarnib, mean survival is extended by about 2.5 years (Gordon et al., 2018). The earlier treatment is started, the longer survival may be.
One important feature of HGPS is that intelligence is normal. Patients can receive age-appropriate education in regular schools, and emotional·social development also takes place within the normal range. Psychologically, as patients become aware of their disease, some experience anxiety, depression, and fear of death, so regular psychological support and family counseling are important. Physical therapy, occupational therapy, and assistive devices help alleviate difficulties in school life caused by physical limitations (joint contractures, failure to thrive). Many HGPS patients and their families connect with each other through patient support organizations (Progeria Research Foundation, etc.) to share information and gain opportunities to participate in clinical trials.
Because most HGPS arises from new mutations, primary prevention is practically impossible. Because there are no carrier parents, family history-based screening is also not applicable. Preimplantation genetic testing (PGT) is theoretically possible, but because HGPS patients do not survive to an age at which they could become pregnant, there is no practical need for its application. Because recurrence due to parental germline mosaicism is reported extremely rarely, prenatal genetic testing may be considered in the next pregnancy for parents who have a child with HGPS, but the likelihood of recurrence is very low (estimated at less than 1%).
Early diagnosis is important because it brings forward the start of early lonafarnib administration and measures to prevent cardiovascular complications. It is currently recommended to start lonafarnib treatment immediately upon diagnosis and to give low-dose aspirin (antiplatelet effect) and statins (lipid improvement and anti-inflammatory effect). Adequate calorie and protein supply through dietary management, prevention of joint contractures through regular physical therapy, and regular monitoring of cardiovascular status (carotid ultrasound and echocardiography every 6–12 months) are needed. Oral care (dental crowding, oral hygiene) and vision·hearing tests are also performed regularly. Psychological support for the whole family and a collaborative system with the palliative care team are established early to support decision-making in the terminal stage.